Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2020 Dec 8;20(2):274–283. doi: 10.1158/1535-7163.MCT-20-0567

Figure 4. Leflunomide inhibited the development of lung adenocarcinoma in an immune-competent GEMM.

Figure 4.

(A) Scheme of the rolling enrollment pre-clinical trial design. LV-Cre: intratracheal delivery of Cre-GFP lentivirus. (B) BLI image of the control and treated mice at the end of the treatment cycle. (C) BLI score for mice at the time of enrollment (Enroll) and the end of the treatment cycle (Final). (D) Animal weight measured at the time of enrollment and the end of the treatment cycle.